Thomas Schmidt - Evaxion Biotech Interim Officer
| EVAX Stock | USD 1.57 0.04 2.48% |
Executive
Thomas Schmidt is Interim Officer of Evaxion Biotech AS
| Age | 53 |
| Address | Dr. Neergaards Vej, Horsholm, Denmark, 2970 |
| Phone | 45 31 31 97 53 |
| Web | https://www.evaxion-biotech.com |
Evaxion Biotech Management Efficiency
The company has return on total asset (ROA) of (0.6945) % which means that it has lost $0.6945 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.028) %, meaning that it created substantial loss on money invested by shareholders. Evaxion Biotech's management efficiency ratios could be used to measure how well Evaxion Biotech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to rise to 4.91 in 2024, whereas Return On Tangible Assets are likely to drop (1.80) in 2024. At this time, Evaxion Biotech's Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 2.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3.4 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Daniel MBA | Biodexa Pharmaceticals | N/A | |
| Andrew Funderburk | Monte Rosa Therapeutics | N/A | |
| James Wang | Virax Biolabs Group | N/A | |
| Melda Oconnell | ZyVersa Therapeutics | N/A | |
| Alan Freidman | Transcode Therapeutics | N/A | |
| Theresa Lowry | Zura Bio Limited | 50 | |
| MD FACC | ZyVersa Therapeutics | 74 | |
| David Brady | Zura Bio Limited | N/A | |
| Gary Whale | Zura Bio Limited | 50 | |
| Kimberly Davis | Zura Bio Limited | 56 | |
| Dmitry MD | Biodexa Pharmaceticals | 44 | |
| Matthew JD | Lyell Immunopharma | 48 | |
| Sandra Vedrick | Revelation Biosciences | N/A | |
| Calais Pharm | Transcode Therapeutics | 65 | |
| Alexander Epshinsky | Allarity Therapeutics | 41 | |
| Xiaolin Wang | Revolution Medicines | 53 | |
| Linda Mahoney | Phio Pharmaceuticals Corp | N/A | |
| Clement Monteil | Virax Biolabs Group | N/A | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Nigel MSc | Virax Biolabs Group | 59 | |
| Magnus DPHIL | Monte Rosa Therapeutics | N/A | |
Management Performance
| Return On Equity | -8.03 | ||||
| Return On Asset | -0.69 |
Evaxion Biotech AS Leadership Team
Elected by the shareholders, the Evaxion Biotech's board of directors comprises two types of representatives: Evaxion Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Evaxion. The board's role is to monitor Evaxion Biotech's management team and ensure that shareholders' interests are well served. Evaxion Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Evaxion Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| DMSC MD, Chief Officer | ||
| Christian MSc, Chief Officer | ||
| Jrgen EMBA, Head Board | ||
| Bo Karmark, Chief Officer | ||
| Jesper Nissen, Chief Officer | ||
| Thomas Schmidt, Interim Officer | ||
| Jesper MSc, Interim COO | ||
| Per Norlen, Chief Officer | ||
| Niels MD, VP CoFounder | ||
| Birgitte Rono, Chief Officer | ||
| Andreas Mattsson, CoFounder Officer |
Evaxion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Evaxion Biotech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -8.03 | ||||
| Return On Asset | -0.69 | ||||
| Operating Margin | (0.57) % | ||||
| Current Valuation | 11.71 M | ||||
| Shares Outstanding | 5.58 M | ||||
| Shares Owned By Insiders | 25.20 % | ||||
| Shares Owned By Institutions | 8.16 % | ||||
| Number Of Shares Shorted | 36.02 K | ||||
| Price To Book | 124.46 X | ||||
| Price To Sales | 2.80 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Evaxion Stock Analysis
When running Evaxion Biotech's price analysis, check to measure Evaxion Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evaxion Biotech is operating at the current time. Most of Evaxion Biotech's value examination focuses on studying past and present price action to predict the probability of Evaxion Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evaxion Biotech's price. Additionally, you may evaluate how the addition of Evaxion Biotech to your portfolios can decrease your overall portfolio volatility.